Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy

Journal of Clinical Investigation

Volumn 115, Issue 6, 2005, Pages 1492-1502

  Tai, Isabella T ^a,b   Dai, Meiru ^b   Owen, David A ^a   Chen, Lan Bo ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; IRINOTECAN; OSTEONECTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER RESISTANCE; COLON CANCER; COLORECTAL CANCER; CONTROLLED STUDY; DNA MICROARRAY; DRUG SENSITIZATION; GENE EXPRESSION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIVITY; THERAPY RESISTANCE; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CELL LINE, TUMOR; COLONIC NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OSTEONECTIN; TRANSPLANTATION, HETEROLOGOUS;

EID: 20444461133     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI23002     Document Type: Article

References (46)

1. de las Alas, M.M., Aebi, S., Fink, D., Howell, S.B., and Los, G. 1997. Loss of DNA mismatch repair: effects on the rate of mutation to drug resistance. J. Natl. Cancer Inst. 89:1537-1541.
2. Tang, R., et al. 2004. p53 is an independent pretreatment markers for long-term survival in stage II and III colorectal cancers: an analysis of interaction between genetic markers and fluorouracil-based adjuvant therapy. Cancer Lett. 210:101-109.
3. Ahnen, D.J., et al. 1998. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. Cancer Res. 58:1149-1158.
4. Bunz, F., et al. 1998. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science. 282:1497-1501.
5. Bunz, F., et al. 1999. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J. Clin. Invest. 104:263-269.
6. Waldman, T., Lengauer, C., Kinzler, K.W., and Vogelstein, B. 1996. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature. 381:713-716.
7. Johnston, P.G., et al. 1995. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res. 55:1407-1412.
8. Edler, D., et al. 2002. Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. J. Clin. Oncol. 20:1721-1728.
9. Edler, D., et al. 2000. Immunohistochemically detected thymidylate synthase in colorectal cancer: an independent prognostic factor of survival. Clin. Cancer Res. 6:488-492.
10. Takebe, N., et al, 2001. Retroviral transduction of human dihydropyrimidine dehydrogenase cDNA confers resistance to 5-fluorouracil in murine hematopoietic progenitor cells and human CD34+-enriched peripheral blood progenitor cells. Cancer Gene Ther. 8:966-973.
11. Salonga, D., et al. 2000, Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin. Cancer Res. 6:1322-1327.
12. Douillard, J.Y., et al. 2000. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. [erratum 2000, 355:1372]. Lancet. 355:1041-1047.
13. Giacchetti, S., et al. 2000. Phase III multicenter randomized trial of oxaliplatin added to chrono-modulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 18:136-147.
14. Candeil, L., et al. 2004. ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases. Int. J. Cancer. 109:848-854.
15. Shirota, Y., et al. 2001. ERCC1 and thymtdylate synthase mRNA levels predict survival for cotorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J. Clin. Oncol 19:4298-4304.
16. Damjanovski, S., Huynh, M.H., Motamed, K., Sage, E.H., and Ringuette, M. 1998. Regulation of SPARC expression during early Xenopus development: evolutionary divergence and conservation of DNA regulatory elements between amphibians and mammals. Dev. Genes Evol. 207:453-461.
17. Martinek, N., Zou, R., Berg, M., Sodek, J., and Ringuette, M. 2002. Evolutionary conservation and association of SPARC with the basal lamina in Drosophila. Dev. Genes Evol. 212:124-133.
18. Termine, J.D., et al. 1981. Osteonectin, a bone-specific protein linking mineral to collagen. Cell. 26:99-105.
19. Tremble, P.M., Lane, T.F., Sage, E.H., and Werb, Z. 1993. SPARC, a secreted protein associated with morphogenesis and tissue remodeling, induces expression of metalloproteinases in fibroblasts through a novel extracellular matrix-dependent pathway. J. Cell Biol. 121:1433-1444.
20. Sage, H, Vernon, R.B., Funk, S.E., Everitt, E.A., and Angello, J. 1989. SPARC, a secreted protein associated with cellular proliferation, inhibits cell spreading in vitro and exhibits Ca+2-dependent binding to the extracellular matrix. J. Cell Biol. 109:341-356.
21. Hasselaar, P., and Sage, E.H. 1992. SPARC antagonizes the effect of basic fibroblast growth factor on the migration of bovine aortic endothelial cells. J. Cell. Biochem. 49:272-283.
22. Motamed, K., and Sage, E.H. 1997. Regulation of vascular morphogenesis by the matricellular protein SPARC. Kidney Int. 51:1383-1387.
23. Damjanovski, S., Karp, X., Funk, S., Sage, E.H., and Ringuette, M.J. 1997. Ectopic expression of SPARC in Xenopus embryos interferes with tissue morphogenesis: identification of a bioactive sequence in the C-terminal EF hand. J. Histochem. Cytochem. 45:643-655.
24. Kupprion, C., Motamed, K., and Sage, E.H. 1998. SPARC (BM-4Q, osteonectin) inhibits the mitogenic effect of vascular endothelial growth factor on microvascular endothelial cells. J. Biol. Chem. 273:29635-29640.
25. Vajkoczy, P., et al. 2000. Targeting angiogenesis inhibits tumor infiltration and expression of the pro-invasive protein SPARC. Int. J. Cancer. 87:261-268.
26. Francki, A., et al. 1999. SPARC regulates the expression of collagen type I and transforming growth factor-beta 1 in mesangial cells. J. Biol. Chem. 274:32145-32152.
27. Schiemann, B.J., Neil, J.R., and Schiemann, W.P. 2003. SPARC inhibits epithelial cell proliferation in part through stimulation of the transforming growth factor-beta-signaling system. Mol. Biol. Cell. 14:3977-3988.
28. Francki, A., et al. 2003. SPARC regulates cell cycle progression in mesangial cells via its inhibition of IGF-dependent signaling. J. Cell. Biochem. 88:802-811.
29. Rempel, S.A., Golembieski, W.A., Fisher, J.L., Maile, M., and Nakeff, A. 2001. SPARC modulates cell growth, attachment and migration of U87 glioma cells on brain extracellular matrix proteins. J. Neurooncol 53:149-160.
30. Yiu G.K., et al. 2001. SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells, Am. J. Pathol 159:609-622.
31. Schultz, C., Lemke, N., Ge, S., Golembieski, W.A., and Rempel, S.A. 2002. Secreted protein acidic and rich in cysteine promotes glioma invasion and delays tumor growth in vivo. Cancer Res. 62:6270-6277.
32. Porter, P.L., Sage, E.H., Lane, T.F., Funk, S.E., and Gown, A.M. 1995. Distribution of SPARC in normal and neoplastic human tissue. J. Histochem. Cytochem. 43:791-800.
33. Chlenski, A., et al. 2002. SPARC is a key Schwannian-derived inhibitor controlling neuroblastoma tumor angiogenesis. Cancer Res. 62:7357-7363.
34. Brekken, R.A., et al. 2003. Enhanced growth of tumors in SPARC null mice is associated with changes in the ECM. J. Clin. Invest. 111:487-495. doi:10.1172/JCI200316804.
35. Puolakkainen, P.A., Brekken, R.A., Muneer, S., and Sage, E.H. 2004. Enhanced growth of pancreatic tumors in SPARC-null mice is associated with decreased deposition of extracellular matrix and reduced tumor cell apoptosis. Mol. Cancer Res. 2:215-224.
36. Abeysinghe, H.R., et al. 2003, THY1 expression is associated with tumor suppression of human ovarian cancer. Cancer Genet. Cytogenet. 143:125-132.
37. Funk, S.E., and Sage, E.H. 1991. The Ca2(+)-binding glycoprotein SPARC modulates cell cycle progression in bovine aortic endothelial cells. Proc. Natl. Acad. Sci. U. S. A. 88:2648-2652.
38. Motamed, K., and Sage, E.H. 1998. SPARC inhibits endothelial cell adhesion but not proliferation through a tyrosine phosphorylation-dependent pathway. J. Cell. Biochem. 70:543-552.
39. Raines, E.W., Lane, T.F., Iruela-Arispe, M.L., Ross, R., and Sage, E.H. 1992. The extracellular glycoprotein SPARC interacts with platelet-derived growth factor (PDGF)-AB and -BB and inhibits the binding of PDGF to its receptors. Proc. Natl. Acad. Sci. U. S. A. 89:1281-1285.
40. Motamed, K., et al. 2002. Inhibition of PDGF-stimulated and matrix-mediated proliferation of human vascular smooth muscle cells by SPARC is independent of changes in cell shape or cyclin-dependent kinase inhibitors. J. Cell. Biochem. 84:759-771.
41. Wagner, H.E., et al. 1990. Characterization of the tumorigenic and metastatic potential of a poorly differentiated human colon cancer cell line. Invasion Metastasis. 10:253-266.
42. Li, C., and Hung Wong, W. 2001. Model-based analysis of oligonucleotide arrays: model validation, design issues and standard error application. Genome Biol. 2:research0032.1-research0032.11.
43. Tai, T.C., Claycomb, R., Her, S., Bloom, A.K., and Wong, D.L. 2002. Glucocorticoid responsiveness of the rat phenylechanolamine N-methyltransferase gene. Mol. Pharmacol. 61:1385-1392.
44. Sun, Y., et al. 1999. Molecular cloning and characterization of human trabeculin-alpha, a giant protein defining a new family of actin-binding proteins. J. Biol. Chem. 274:33522-33530.
45. Van, Q., Weaver, M., Perdue, N., and Sage, E.H. 2005. Matricellular protein SPARC is translocated to the nuclei of immortalized murine lens epithelial cells. J. Cell. Physiol. 203:286-294.
46. Signoretti, S., et al. 2000. p63 is a prostate basal cell marker and is required for prostate development. Am. J. Pathol. 157:1769-1775.